Abstract
A retrospective study was conducted to evaluate the efficacy of levofloxacin in the treatment of Stenotrophomonas maltophilia bacteremia. The 30-day mortality rates were similar between the trimerthoprim-sulfamethoxazole (TMP-SMX) and levofloxacin treatment groups. Adverse events related to antibiotics occurred more frequently in patients receiving TMP-SMX, and recurrent bacteremia due to levofloxacin-resistant S. maltophilia strains developed in patients treated with levofloxacin. Our data suggest that levofloxacin can be a useful alternative option for treating S. maltophilia infections.
| Original language | English |
|---|---|
| Pages (from-to) | 581-583 |
| Number of pages | 3 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 58 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2014 |
Fingerprint
Dive into the research topics of 'Can levofloxacin be a useful alternative to trimethoprim-Sulfamethoxazole for treating stenotrophomonas maltophilia bacteremia?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver